Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) CFO Charles N. York II bought 6,500 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was acquired at an average cost of $4.59 per share, with a total value of $29,835.00. Following the transaction, the chief financial officer now owns 10,828 shares of the company’s stock, valued at $49,700.52. The purchase was disclosed in a filing with the SEC, which is available at this link.

Shares of Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) traded down $0.34 during trading on Tuesday, hitting $4.74. The stock had a trading volume of 76,239 shares, compared to its average volume of 65,901. Aeglea Bio Therapeutics Inc has a 1-year low of $2.81 and a 1-year high of $8.14.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.48) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.07. The business had revenue of $1.26 million during the quarter. Aeglea Bio Therapeutics had a negative return on equity of 44.05% and a negative net margin of 527.99%. research analysts expect that Aeglea Bio Therapeutics Inc will post -1.97 EPS for the current year.

Several institutional investors have recently modified their holdings of AGLE. Bank of New York Mellon Corp acquired a new stake in shares of Aeglea Bio Therapeutics in the first quarter worth $157,000. Renaissance Technologies LLC acquired a new stake in shares of Aeglea Bio Therapeutics in the first quarter worth $270,000. Vanguard Group Inc. boosted its position in shares of Aeglea Bio Therapeutics by 9.4% in the second quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock worth $579,000 after buying an additional 12,966 shares during the period. Finally, Susquehanna International Group LLP acquired a new stake in shares of Aeglea Bio Therapeutics in the second quarter worth $653,000. 46.89% of the stock is owned by institutional investors and hedge funds.

Separately, Zacks Investment Research cut Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 19th.

ILLEGAL ACTIVITY WARNING: This story was first posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at

About Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Receive News & Ratings for Aeglea Bio Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics Inc and related companies with's FREE daily email newsletter.